Drug Profile
Navitoclax - AbbVie
Alternative Names: ABT-263; RG 7423; RG 7433Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer Abbott Laboratories; AbbVie; Centre hospitalier de l'Universite de Montreal; Genentech; National Cancer Institute (USA); Princess Margaret Hospital (University of Toronto); Sunnybrook Health Sciences Centre
- Class Antifibrotics; Antineoplastics; Benzamides; Morpholines; Piperazines; Senotherapeutics; Small molecules; Sulfones
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Myelofibrosis
- Phase I/II Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Phase I Haematological malignancies; Ovarian cancer; Triple negative breast cancer
- Preclinical Colorectal cancer; Head and neck cancer; Idiopathic pulmonary fibrosis; Vascular disorders
- No development reported Crohn's disease
- Discontinued Chronic lymphocytic leukaemia; Lymphoid leukaemia; Lymphoma; Non-small cell lung cancer; Small cell lung cancer
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Myelofibrosis(Combination therapy) in USA (PO, Tablet)
- 18 Jan 2024 Efficay, adverse events and drug interaction data from a phase I trial in Solid tumours presented at the 2024 Gastrointestinal Cancers Symposium, 2024 (ASCO-GCS-2024)
- 11 Dec 2023 Updated safety and efficacy data from a phase III TRANSFORM-1 trial in Myelofibrosis released by AbbVie